Thomas Wayne Gibbs
Directeur/Membre du Conseil chez Biocartis SA
Profil
Thomas Wayne Gibbs is a professional with current positions as Non-Executive Director at Immunexpress Pty Ltd., Director at Biocartis SA, Non-Executive Director at Immunexpress, Inc., and Director at Debiopharm Innovation Fund.
He has held former positions as Director at Molecular Devices LLC, Director at Delta Biotechnology Ltd., Director-Business Development & Licensing at Diagnoplex SA, Director at GenePOC, Inc., Principal at Covalys Biosciences AG, and Principal at Med Discovery SA. He holds a doctorate degree from the University of Warwick.
Postes actifs de Thomas Wayne Gibbs
| Sociétés | Poste | Début |
|---|---|---|
Biocartis SA
 Biocartis SA Medical SpecialtiesHealth Technology Biocartis SA develops molecular diagnostic solutions. It focuses on Oncology. The firm’s products include Idylla and Oncology assays and mutation tests. It also provides instant access to personalized medicine for patients. The company was founded by Rudi Pauwels in 2007 and is headquartered in Lausanne, Switzerland. | Directeur/Membre du Conseil | - |
Immunexpress Pty Ltd.
 Immunexpress Pty Ltd. Medical SpecialtiesHealth Technology Immunexpress Pty Ltd. engages in creating molecular diagnostics for sepsis. The company was founded by Roslyn Brandon, Mervyn Rees Thomas and Richard Bruce Brandon and in 2006 and is headquartered in Toowong, Australia. | Directeur/Membre du Conseil | - |
Debiopharm Innovation Fund /Management/
 Debiopharm Innovation Fund /Management/ Investment ManagersFinance Debiopharm Innovation Fund SA develops, manufactures, and markets diagnostic systems. It seeks to invest in the biotechnology, diagnostics, and pharmaceutical industries with a focus on biomarker development, and large molecule capabilities. The firm mission is to invest in innovative diagnostic companies developing platforms and content to complement in-house diagnostic activities, give insight into cutting-edge diagnostics and facilitate access to new technologies. The company was founded in 1979 and is headquartered in Fribourg, Switzerland. | Directeur/Membre du Conseil | - |
Immunexpress, Inc.
 Immunexpress, Inc. Miscellaneous Commercial ServicesCommercial Services Immunexpress, Inc. engages in development of revolutionary molecular diagnostics. The firm's SeptiCyte technology quantifies specific and multiple molecular markers from the patient?s own immune system for earlier detection and severity assessment of sepsis, as well as the better timing of drugs and other therapies. The company was founded by Richard Bruce Brandon, Roslyn Brandon and Mervyn Rees Thomas in and is headquartered in | Directeur/Membre du Conseil | - |
Anciens postes connus de Thomas Wayne Gibbs
| Sociétés | Poste | Fin |
|---|---|---|
GenePOC, Inc.
 GenePOC, Inc. Medical SpecialtiesHealth Technology GenePOC, Inc. develops rapid molecular devices to detect genes at point-of-care. Its product includes an integrated portable instrument for the prevention and early detection of infectious diseases based on a centripetal technology platform. Its product also includes GenePOC disposable, a device for performing nucleic acid-based diagnostics at POC. The company’s products are also used for infectious disease, rapid food microbiology, and human pharmacogenetic testing applications. The company was founded by Michel G. Bergeron in 2007 and is headquartered in Quebec, Canada. | Directeur/Membre du Conseil | - |
Med Discovery SA
 Med Discovery SA BiotechnologyHealth Technology Med Discovery SA is a Swiss biopharmaceutical company that develops treatments for cancers. The private company was founded by David Luc Deperthes. | Corporate Officer/Principal | - |
Covalys Biosciences AG
 Covalys Biosciences AG Medical SpecialtiesHealth Technology Covalys Biosciences AG develops and produces tools for protein research. The company was founded by Patrik Siedler, Maik Kindermann, Christoph Bieri, Henri Zinsli and Nils Johnsson in June 2002 and is headquartered in Witterswil, Switzerland. | Corporate Officer/Principal | - |
Diagnoplex SA
 Diagnoplex SA Medical SpecialtiesHealth Technology Diagnoplex SA develops molecular diagnostics for colon cancer. It lead product, Colox is a minimally-invasive blood test developed for the systematic screening and detection of early and advanced colorectal cancer. The company was founded in April 2005 by Stavros Therianos, Curzio Roberto Maria Rüegg, Jacques R. Essinger and Jean-Pierre Rosat and is headquartered in Lausanne, Switzerland. | Corporate Officer/Principal | - |
Molecular Devices LLC
 Molecular Devices LLC Medical SpecialtiesHealth Technology Molecular Devices LLC engages in the provision of bioanalytical solutions for protein and cell biology in life science research, pharmaceutical, and bio-therapeutic development. Its product portfolio includes platforms for screening, genomic and cellular analysis, colony selection, and microplate detection. The company was founded by Harden M. McConnell in July, 1983 and is headquartered in San Jose, CA. | Directeur/Membre du Conseil | - |
Formation de Thomas Wayne Gibbs
| University of Warwick | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 10 |
|---|---|
Molecular Devices LLC
Molecular Devices LLC Medical SpecialtiesHealth Technology Molecular Devices LLC engages in the provision of bioanalytical solutions for protein and cell biology in life science research, pharmaceutical, and bio-therapeutic development. Its product portfolio includes platforms for screening, genomic and cellular analysis, colony selection, and microplate detection. The company was founded by Harden M. McConnell in July, 1983 and is headquartered in San Jose, CA. | Health Technology |
Delta Biotechnology Ltd.
 Delta Biotechnology Ltd. Pharmaceuticals: OtherHealth Technology Part of Novonesis A/S, Delta Biotechnology Ltd. is a British company that produces and markets a range of valuable proteins from yeast using low-cost manufacturing technologies. The company is based in Windlesham, UK. Delta Biotechnology was acquired by Novozymes A/S on July 06, 2006. | Health Technology |
Covalys Biosciences AG
Covalys Biosciences AG Medical SpecialtiesHealth Technology Covalys Biosciences AG develops and produces tools for protein research. The company was founded by Patrik Siedler, Maik Kindermann, Christoph Bieri, Henri Zinsli and Nils Johnsson in June 2002 and is headquartered in Witterswil, Switzerland. | Health Technology |
Immunexpress Pty Ltd.
Immunexpress Pty Ltd. Medical SpecialtiesHealth Technology Immunexpress Pty Ltd. engages in creating molecular diagnostics for sepsis. The company was founded by Roslyn Brandon, Mervyn Rees Thomas and Richard Bruce Brandon and in 2006 and is headquartered in Toowong, Australia. | Health Technology |
Diagnoplex SA
Diagnoplex SA Medical SpecialtiesHealth Technology Diagnoplex SA develops molecular diagnostics for colon cancer. It lead product, Colox is a minimally-invasive blood test developed for the systematic screening and detection of early and advanced colorectal cancer. The company was founded in April 2005 by Stavros Therianos, Curzio Roberto Maria Rüegg, Jacques R. Essinger and Jean-Pierre Rosat and is headquartered in Lausanne, Switzerland. | Health Technology |
Biocartis SA
Biocartis SA Medical SpecialtiesHealth Technology Biocartis SA develops molecular diagnostic solutions. It focuses on Oncology. The firm’s products include Idylla and Oncology assays and mutation tests. It also provides instant access to personalized medicine for patients. The company was founded by Rudi Pauwels in 2007 and is headquartered in Lausanne, Switzerland. | Health Technology |
GenePOC, Inc.
GenePOC, Inc. Medical SpecialtiesHealth Technology GenePOC, Inc. develops rapid molecular devices to detect genes at point-of-care. Its product includes an integrated portable instrument for the prevention and early detection of infectious diseases based on a centripetal technology platform. Its product also includes GenePOC disposable, a device for performing nucleic acid-based diagnostics at POC. The company’s products are also used for infectious disease, rapid food microbiology, and human pharmacogenetic testing applications. The company was founded by Michel G. Bergeron in 2007 and is headquartered in Quebec, Canada. | Health Technology |
Med Discovery SA
Med Discovery SA BiotechnologyHealth Technology Med Discovery SA is a Swiss biopharmaceutical company that develops treatments for cancers. The private company was founded by David Luc Deperthes. | Health Technology |
Immunexpress, Inc.
Immunexpress, Inc. Miscellaneous Commercial ServicesCommercial Services Immunexpress, Inc. engages in development of revolutionary molecular diagnostics. The firm's SeptiCyte technology quantifies specific and multiple molecular markers from the patient?s own immune system for earlier detection and severity assessment of sepsis, as well as the better timing of drugs and other therapies. The company was founded by Richard Bruce Brandon, Roslyn Brandon and Mervyn Rees Thomas in and is headquartered in | Commercial Services |
Debiopharm Innovation Fund /Management/
Debiopharm Innovation Fund /Management/ Investment ManagersFinance Debiopharm Innovation Fund SA develops, manufactures, and markets diagnostic systems. It seeks to invest in the biotechnology, diagnostics, and pharmaceutical industries with a focus on biomarker development, and large molecule capabilities. The firm mission is to invest in innovative diagnostic companies developing platforms and content to complement in-house diagnostic activities, give insight into cutting-edge diagnostics and facilitate access to new technologies. The company was founded in 1979 and is headquartered in Fribourg, Switzerland. | Finance |